CN109758379A - A kind of compound blood coagulation acid composition and preparation method thereof, product - Google Patents
A kind of compound blood coagulation acid composition and preparation method thereof, product Download PDFInfo
- Publication number
- CN109758379A CN109758379A CN201910214162.8A CN201910214162A CN109758379A CN 109758379 A CN109758379 A CN 109758379A CN 201910214162 A CN201910214162 A CN 201910214162A CN 109758379 A CN109758379 A CN 109758379A
- Authority
- CN
- China
- Prior art keywords
- blood coagulation
- acid
- compound
- tranexamic acid
- ascorbyl phosphate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a kind of compound blood coagulation acid compositions, including following weight percentage components: tranexamic acid 0.6-4.0%, Sodium Ascorbyl Phosphate 0.4-3.0%, hydroxyl cyclodextrin 3.0-49.0%, surplus is water.In addition, the invention also discloses preparation methods and product.Compound blood coagulation acid composition obtained by the present invention can effectively improve the percutaneous absorbtion effect of tranexamic acid and Sodium Ascorbyl Phosphate, while the stability of Sodium Ascorbyl Phosphate in a liquid can be improved, and more preferably play the synergistic effect of light spot.
Description
Technical field
The present invention relates to daily-use chemical industry and pharmaceutical technology field more particularly to a kind of compound blood coagulation acid composition and its preparations
Method, product.
Background technique
Just there is the pursuit to beautification itself since human civilization occurs, Nails are all yearned for pale with pursuit health
Skin, at ancient Chinese " loving beauty is part of human nature ", more there are the aesthetic conceptions of " one white hide three ugly " in the modern times.Human skin
Color is mainly determined according to quantity, size and the distribution in Skin Cell containing melanin.Melanin be present in it is each
A kind of protein of application on human skin basal layer.Ultraviolet irradiation can enable melanin generate variation, generate a kind of object for protecting skin
Matter, then melanin moving layer by layer via cell metabolism again, has arrived skin epidermis, form color spot that we are seen and
The irregular equal skin problems of the colour of skin.
In order to realize whitening effect, we should prevent B16 cell first, and at present for inhibition tyrosinase (TYR)
Active research is more.Tyrosinase is a kind of enzyme that melanin biosynthesis plays key effect in the process, it affects black
The forming process of pigment, level of activity play main function to the quantity and deposition of melanin.Whitening agent type on the market
Very much, and wherein it is black to pass through the oxidation reaction reduction for inhibiting tyrosinase activity or blocking and generate melanin from tyrosine for a major class
The generation of pigment achievees the effect that skin-whitening.
Tranexamic acid, also known as Trenaxmine, tranexamic acid, lightening mechanism are to inhibit to lead to while the activity of tyrosinase
It crosses and plasminogen is inhibited to be converted into fibrinolysin and interfere the connection between melanocyte and keratinocyte, to reduce melanin
Cell generates melanin, and the situation of melanin agglutination is removed since spot edge, and this mechanism of action worked along both lines makes
Tranexamic acid ensure that the effect of whitening.Blood coagulation Acidity is stablized, and does not destroy vulnerable to temperature environment, the multiple advantages such as nonirritant,
Its move back it is black except spot the effect of it is about 50 times higher than vitamin C, be nearly 10 times of tartaric acid or so.But tranexamic acid transdermal effect is poor, commonly
External preparation local application percutaneous absorbtion is limited, and external application onset time is slow, and whitening effect is also undesirable.Most of patients uses at present
Intravenous drip or oral tranexamic acid reach whitening function.Ye You document report South Korea LeeJH is solidifying using local intradermal microinjection
Hematic acid treats chloasma, obtains certain whitening effect, but this method must apply local anesthetic, using being inconvenient.Wu Tingyan
Nanometer micropin introductory technique is then used, the percutaneous absorbtion of tranexamic acid is promoted, treatment skin of face is obscure, certain curative effect is obtained, but
This method needs professional person to use, and there are problems inconvenient to use.
Sodium Ascorbyl Phosphate also known as be sodium ascorbyl phosphate, be a kind of vitamin C derivatives, had proven to compared with
Good photoprotection and depigmentaton deposition, lightening mechanism are the black that dark melanin reduction is become to light color
Element inhibits intermediate to generate melanin.After skin absorbs, Sodium Ascorbyl Phosphate is decomposed in skin, releases active dimension
Raw element C can be reasonably resistant to ultraviolet light invasion, and can capture oxygen radical, promote collagen to generate, can effectively prevent pigment
Calmness dispels various skin splash, and skin moisturizing can be made bright and clean, pale penetrating.Sodium Ascorbyl Phosphate is compared with vitamin C
Property is relatively stable, but has experiment to show that under certain condition, Sodium Ascorbyl Phosphate still has shakiness in aqueous solution
It is qualitative, it can be oxidized and yellowing phenomenon occur, if being directly appended to will lead to active inactivation in liquid or semi-solid products, thus shadow
Ring its function and effect.
Current whitening composition single on the market or the product of a variety of whitening compositions combination, however in some cases, it uses
A kind of single whitening composition effect is not obvious, in addition various lightening compositions also fail generate people's expected effect and
Occur skin side-effects in some cases.
Summary of the invention
To overcome the problems, such as that existing whitening product effect is undesirable, on the one hand the embodiment of the present invention provides a kind of compound
Blood coagulation acid composition, including following weight percentage components: tranexamic acid 0.6-4.0%, Sodium Ascorbyl Phosphate 0.4-
3.0%, hydroxyl cyclodextrin 3.0-49.0%, surplus is water.
On the other hand the embodiment of the present invention provides a kind of compound blood coagulation acid composition, the group including following weight percent
Point: tranexamic acid 1.0-3.0%, Sodium Ascorbyl Phosphate 0.6-2.4%, hydroxyl cyclodextrin 4.8-32.4%, surplus is water.
On the other hand the embodiment of the present invention provides a kind of preparation method of compound blood coagulation acid composition, be used to prepare above-mentioned
Described in any item compound blood coagulation acid compositions, which comprises
Sodium Ascorbyl Phosphate, hydroxyl cyclodextrin are placed in the water that temperature is 20 DEG C -40 DEG C, stirring to dissolution, after
Continuous stirring 0.5 hour, obtains stirring solution；
Tranexamic acid is added in the stirring solution, stirring 0.5-2 hours is continued, filtering obtains compound tranexamic acid
Composition.
On the other hand the embodiment of the present invention provides a kind of compound blood coagulation acid solution dosage formulations of external application, by any of the above-described institute
The compound blood coagulation acid composition stated is prepared.
Further, above-mentioned compound blood coagulation acid solution dosage formulations further include moisturizer and preservative, the moisturizer include glycerol,
Propylene glycol, butanediol or pyrrolidone sodium carboxylate, the preservative include Phenoxyethanol or methylparaben.
Finally, the embodiment of the invention also provides a kind of compound tranexamic acid gel preparations of external application, by any of the above-described institute
The compound blood coagulation acid composition stated is prepared.
Further, above-mentioned compound tranexamic acid gel preparation further includes moisturizer, thickener and preservative, the moisturizer packet
Include glycerol, the thickener includes hyaluronic acid and hypromellose, propylene glycol, butanediol or pyrrolidone sodium carboxylate,
The preservative includes Phenoxyethanol or methylparaben.
The embodiment of the present invention, can be with to the light spot of skin by the way that both tranexamic acid and Sodium Ascorbyl Phosphate to be used in combination
Play synergistic effect.For tranexamic acid poor permeability, it is not easy directly to be absorbed by skin and Sodium Ascorbyl Phosphate is unstable
Disadvantage, the embodiment of the present invention under certain condition, are distinguished tranexamic acid and Sodium Ascorbyl Phosphate using hydroxypropyl cyclodextrin
It is included, improves the percutaneous absorbtion effect of tranexamic acid, overcome that Sodium Ascorbyl Phosphate stability is poor, easy in inactivation lacks
It falls into, to improve stability of the Sodium Ascorbyl Phosphate in solution and semisolid preparation, the synergy for being easy to play light spot is made
With.
Detailed description of the invention
To describe the technical solutions in the embodiments of the present invention more clearly, make required in being described below to embodiment
Attached drawing is briefly described, it should be apparent that, drawings in the following description are only some embodiments of the invention, for
For those of ordinary skill in the art, without creative efforts, it can also be obtained according to these attached drawings other
Attached drawing.
Fig. 1 is the compound blood coagulation acid composition of first embodiment of the invention and the compound tranexamic acid solution for comparing embodiment
The curve graph of drug transdermal amount at any time.
Specific embodiment
In order to which the technical problems, technical solutions and beneficial effects solved by the present invention is more clearly understood, below in conjunction with
Accompanying drawings and embodiments, the present invention will be described in further detail.It should be appreciated that specific embodiment described herein is only used
To explain the present invention, it is not intended to limit the present invention.
First embodiment:
The component of the compound tranexamic acid solution (in terms of 1000 parts of quality, every part contains tranexamic acid 3%) of the embodiment of the present invention:
15 parts of tranexamic acid, 7 parts of Sodium Ascorbyl Phosphate, 70 parts of hydroxyl cyclodextrin, 20 parts of glycerol, 20 parts of propylene glycol, 30 parts of butanediol,
15 parts of pyrrolidone sodium carboxylate, 6 parts of Phenoxyethanol, 5 parts and 812 parts of water of methylparaben.
Preparation method is:
(1) Sodium Ascorbyl Phosphate, hydroxyl cyclodextrin are placed in 408 parts of water that temperature is 40 DEG C, stirring to dissolution,
Continue stirring 0.5 hour.
(2) tranexamic acid is added in above-mentioned stirring solution, continue stirring 1.5 hours, add glycerol, propylene glycol,
Butanediol, pyrrolidone sodium carboxylate, Phenoxyethanol and methylparaben, stirring to dissolution to get.
The embodiment of the present invention is based on tranexamic acid inclusion compound ingredient, Sodium Ascorbyl Phosphate inclusion compound of arranging in pairs or groups, preparation one
The light spot composition of kind is applied to skin whitening in a manner of percutaneous absorbtion.
Compound blood coagulation acid solution dosage formulations of the present invention include but is not limited to face cleaning gel, face cleaning water, profit body essence, essence
Hua Su, stoste, toner, smoothing toner, soft peptide water of moistening, shower cream, spraying and facial mask.
Second embodiment:
The component of the compound tranexamic acid solution (in terms of 1000 parts of quality, every part contains tranexamic acid 1%) of the embodiment of the present invention:
5 parts of tranexamic acid, 3 parts of Sodium Ascorbyl Phosphate, 24 parts of hydroxyl cyclodextrin, 20 parts of glycerol, 20 parts of propylene glycol, 30 parts of butanediol,
15 parts of pyrrolidone sodium carboxylate, 6 parts of Phenoxyethanol, 5 parts and 872 parts of water of methylparaben.
Preparation method is:
(1) Sodium Ascorbyl Phosphate, hydroxyl cyclodextrin are placed in 468 parts of water that temperature is 25 DEG C, stirring to dissolution,
Continue stirring 0.5 hour.
(2) tranexamic acid is added in above-mentioned stirring solution, continues stirring 0.5 hour, then be separately added into glycerol, the third two
Alcohol, butanediol, pyrrolidone sodium carboxylate, Phenoxyethanol, methylparaben and remaining water, stirring to dissolution to get.
3rd embodiment:
The group of the compound blood coagulation acid gel agent (in terms of 1000 parts of quality, every part contains tranexamic acid 1.5%) of the embodiment of the present invention
Point: 7.5 parts of tranexamic acid, 12 parts of Sodium Ascorbyl Phosphate, 160 parts of hydroxyl cyclodextrin, 20 parts of glycerol, 20 parts of propylene glycol, fourth two
30 parts of alcohol, 15 parts of pyrrolidone sodium carboxylate, 6 parts of Phenoxyethanol, 5 parts of methylparaben, 9 parts of hyaluronic acid, hydroxypropyl methylcellulose
1 part and 714.5 parts of water of element.
Compound tranexamic acid gel preparation of the present invention include but is not limited to facial cleanser, face cream, emollient cream, massage cream,
Eye cream, Run Tishuan, cleansing cream, mildy wash, face cleaning foam, profit body cream, purificant, gel, creams, facial mask, ointment and other beauty
Hold paste.
Preparation method is:
(1) Sodium Ascorbyl Phosphate, hydroxyl cyclodextrin are placed in 320 parts of water that temperature is 30 DEG C, stirring to dissolution,
Continue stirring 0.5 hour.
(2) tranexamic acid is added in above-mentioned stirring solution, continues stirring 2.0 hours, then be separately added into glycerol, the third two
Alcohol, butanediol, pyrrolidone sodium carboxylate, Phenoxyethanol, methylparaben and hyaluronic acid, stirring to dissolution to get.
Preparation method disclosed in foregoing invention embodiment is simple, and energy consumption is small, and production cost is low, it is easy to accomplish the big life of serialization
It produces, obtained compound blood coagulation acid composition can effectively improve the percutaneous absorbtion effect of tranexamic acid and Sodium Ascorbyl Phosphate
Fruit, while the stability of Sodium Ascorbyl Phosphate in a liquid can be improved, more preferably play the synergistic effect of light spot.
Fourth embodiment:
The embodiment of the invention provides a kind of compound blood coagulation acid compositions, including following weight percentage components: blood coagulation
Sour 0.6-4.0%, Sodium Ascorbyl Phosphate 0.4-3.0%, hydroxyl cyclodextrin 3.0-49.0%, surplus is water.
It should be noted that the present composition can be used for preparing the liquid preparation of above-described embodiment, gelling agent etc..
The embodiment of the present invention, can be with to the light spot of skin by the way that both tranexamic acid and Sodium Ascorbyl Phosphate to be used in combination
Play synergistic effect.For tranexamic acid poor permeability, it is not easy directly to be absorbed by skin and Sodium Ascorbyl Phosphate is unstable
Disadvantage, the embodiment of the present invention under certain condition, are distinguished tranexamic acid and Sodium Ascorbyl Phosphate using hydroxypropyl cyclodextrin
It is included, improves the percutaneous absorbtion effect of tranexamic acid, overcome that Sodium Ascorbyl Phosphate stability is poor, easy in inactivation lacks
It falls into, to improve stability of the Sodium Ascorbyl Phosphate in solution and semisolid preparation, the synergy for being easy to play light spot is made
With.
Comparative example:
The component of the compound tranexamic acid solution (in terms of 1000 parts, every part contains tranexamic acid 1%) of the present embodiment: tranexamic acid 15
Part, 7 parts of Sodium Ascorbyl Phosphate, 20 parts of glycerol, 20 parts of propylene glycol, 30 parts of butanediol, 15 parts of pyrrolidone sodium carboxylate, benzene oxygen
6 parts of ethyl alcohol, 5 parts and 882 parts of water of methylparaben.
Preparation method is:
Sodium Ascorbyl Phosphate, tranexamic acid are separately added into the water that temperature is 25 DEG C, stirring, then is separately added into sweet
Oil, propylene glycol, butanediol, pyrrolidone sodium carboxylate, Phenoxyethanol, methylparaben and remaining water, stirring to dissolution to get.
In order to better illustrate the present invention the advantages of, below implements the first, second, third embodiment of the invention and comparison
Example is maked a comparison description by penetrating absorption and stability test.
Penetrating absorption:
By Ba-Ma mini pig sacrificed by exsanguination, phenomena such as observation without red swelling of the skin, hyperemia, breakage.Shaving strips pigskin, carefully
Subcutaneous tissue is removed, is cleaned with physiological saline, is set in -70 DEG C of refrigerators and freeze, it is spare.
The abdomen pigskin handled well is taken, is thawed at normal temperature, required fritter is cut into, cleaned with physiological saline and is inhaled with filter paper
The moisture of dry pigskin upper and lower surface, is separately fixed at Franz diffusion cell, makes horny layer of epidermis upward, and pigskin following table face contact expands
Pond liquid level is dissipated, carries out Transdermal Absorption test by Ligustrazine hydrochloride test requirements document.Fill it up with physiological saline in reception tank, 37
± 0.1 DEG C of heating water bath balances 1h under the conditions of constant speed magnetic agitation (300 ± 5r/min), is separately added into first to supply chamber
Each 1mL of compound blood coagulation acid solution, is sealed with sealant made from embodiment and comparative example, to prevent solvent evaporation.Respectively at
2,4,6,8,10,12h pipettes receiving liquid 1.0mL, with 0.22 μm of filtering with microporous membrane, refills the spare receiving liquid of 1.0mL immediately, inhales
It takes 20 μ L filtrates to be measured with HPLC sample introduction, calculates the drug accumulation transit dose (Q) of each time point (h).As a result Fig. 1 is please referred to.
As shown in Figure 1, the compound blood coagulation acid solution of two embodiments has a Transdermal absorption effect in 12h, energy when 2h
Through abdomen pigskin, and unit area Percutaneous permeability extends at any time and increases.But first embodiment is opened from penetrating absorption
Stage beginning just shows biggish advantage, and the transit dose at each time point is all significantly higher than comparative example in 12h.
Stability test
Compound blood coagulation acid supplement made from the first, second, third embodiment and comparative example is taken to do stability experiment, it will
Compound blood coagulation acid supplement is respectively placed in the stability test case that indoor and temperature is 40 DEG C, is placed 0-6 months.It the results are shown in Table
One.
Each embodiment quality control assays result of table 1
As can be seen from Table 1, hydroxyl cyclodextrin is added due to not having in comparative example, in the state not included, room
Mild high temperatures are poorer than embodiment, and as time went on, liquid color changes.Comparative example is in room temperature
When, liquid color becomes yellowish at 6 months；When temperature is 40 degree, 3 months and 6 months liquid colors change, color
Become deep yellow from yellowish.And the first, second, third embodiment has good stability, solution is without color change in 6 months.It says
The bright embodiment of the present invention overcomes that Sodium Ascorbyl Phosphate stability is poor, the defect of easy in inactivation, to improve ascorbic acid phosphorus
Stability of the acid esters sodium in solution and semisolid preparation, is easy to play the synergistic effect of light spot.
Above-described specific embodiment has carried out further the purpose of the present invention, technical scheme and beneficial effects
It is described in detail, is not intended to limit the invention.Any modification done within the spirit and principles of the present invention, equivalent replacement
With improve etc., should all be included in the protection scope of the present invention.
Claims (7)
1. a kind of compound blood coagulation acid composition, which is characterized in that including following weight percentage components: tranexamic acid 0.6-
4.0%, Sodium Ascorbyl Phosphate 0.4-3.0%, hydroxyl cyclodextrin 3.0-49.0%, surplus is water.
2. a kind of compound blood coagulation acid composition, which is characterized in that including following weight percentage components: tranexamic acid 1.0-
3.0%, Sodium Ascorbyl Phosphate 0.6-2.4%, hydroxyl cyclodextrin 4.8-32.4%, surplus is water.
3. according to claim 1 or the preparation method of the 2 compound blood coagulation acid compositions, which is characterized in that the method packet
It includes:
Sodium Ascorbyl Phosphate, hydroxyl cyclodextrin are placed in the water that temperature is 20 DEG C -40 DEG C, stirring continues to stir to dissolving
It mixes 0.5 hour, obtains stirring solution；
Tranexamic acid is added in the stirring solution, stirring 0.5-2 hours is continued, filtering obtains the combination of compound tranexamic acid
Object.
4. a kind of compound blood coagulation acid solution dosage formulations of external application, which is characterized in that described in any item multiple by claim 1 to 3
Square blood coagulation acid composition is prepared.
5. the compound blood coagulation acid solution dosage formulations of external application according to claim 4, which is characterized in that further include moisturizer and anti-
Rotten agent, the moisturizer include glycerol, propylene glycol, butanediol or pyrrolidone sodium carboxylate, and the preservative includes Phenoxyethanol
Or methylparaben.
6. a kind of compound tranexamic acid gel preparation of external application, which is characterized in that described in any item multiple by claim 1 to 3
Square blood coagulation acid composition is prepared.
7. the compound tranexamic acid gel preparation of external application according to claim 6, which is characterized in that further include moisturizer, increase
Thick dose and preservative, the moisturizer include that glycerol, the thickener include hyaluronic acid and hypromellose, the third two
Alcohol, butanediol or pyrrolidone sodium carboxylate, the preservative include Phenoxyethanol or methylparaben.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910214162.8A CN109758379A (en) | 2019-03-20 | 2019-03-20 | A kind of compound blood coagulation acid composition and preparation method thereof, product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910214162.8A CN109758379A (en) | 2019-03-20 | 2019-03-20 | A kind of compound blood coagulation acid composition and preparation method thereof, product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109758379A true CN109758379A (en) | 2019-05-17 |
Family
ID=66459556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910214162.8A Pending CN109758379A (en) | 2019-03-20 | 2019-03-20 | A kind of compound blood coagulation acid composition and preparation method thereof, product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109758379A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113559005A (en) * | 2021-08-02 | 2021-10-29 | 成都卓阳生物科技有限公司 | Tranexamic acid glutathione compound aqueous solution and preparation method thereof |
Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4465662A (en) * | 1980-04-08 | 1984-08-14 | Lion Corporation | Oral compositions of tranexamic acid and carvone |
| JPH01305009A (en) * | 1988-05-31 | 1989-12-08 | Showa Denko Kk | Cosmetic additive |
| JPH1067639A (en) * | 1996-08-26 | 1998-03-10 | Shiseido Co Ltd | Vitamin e-vitamin c phosphoric diester/cyclodextrin clathrate and external preparation for skin containing the same |
| KR20000038845A (en) * | 1998-12-09 | 2000-07-05 | 이현순 | Improved stability of water in oil type emulsion cosmetic composition comprising l-ascorbic acid and manufacturing method thereof |
| JP2006008550A (en) * | 2004-06-23 | 2006-01-12 | Shiseido Co Ltd | Antiaging agent |
| JP2007055943A (en) * | 2005-08-25 | 2007-03-08 | Kyoei Kagaku Kogyo Kk | Ascorbic acid 2-phosphate magnesium composition and cosmetic containing the same |
| CN101757621A (en) * | 2008-11-28 | 2010-06-30 | 天津金耀集团有限公司 | Cyclodextrin inclusion drug composition for ocular inflammation resistance |
| KR20100127580A (en) * | 2009-05-26 | 2010-12-06 | (주)바이오제닉스 | Cosmetic composition having stabilized derivatives of vitamin c and method for fabricating the same |
| CN101938988A (en) * | 2008-02-08 | 2011-01-05 | 株式会社资生堂 | Skin whitening agent and external preparation for the skin |
| CN102274145A (en) * | 2011-08-05 | 2011-12-14 | 广东南方洁灵科技实业有限公司 | Composite cyclodextrin clathrate of licorice flavones and ferulic acid and preparation method and applications thereof |
| KR20120041074A (en) * | 2010-10-20 | 2012-04-30 | 주식회사 동구제약 | Pharmaceutical composition containing ascorbic acid and tranexamic acid having enhanced stability |
| US20180116986A1 (en) * | 2016-10-28 | 2018-05-03 | Hemant N. Joshi | Composition of novel powder formulations of tranexamic acid |
| CN108295080A (en) * | 2018-03-15 | 2018-07-20 | 山东滨州智源生物科技有限公司 | A kind of preparation method of salicylic acid HYDROXYPROPYL BETA-CYCLODEXTRIN inclusion compound |
-
2019
- 2019-03-20 CN CN201910214162.8A patent/CN109758379A/en active Pending
Patent Citations (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4465662A (en) * | 1980-04-08 | 1984-08-14 | Lion Corporation | Oral compositions of tranexamic acid and carvone |
| JPH01305009A (en) * | 1988-05-31 | 1989-12-08 | Showa Denko Kk | Cosmetic additive |
| JPH1067639A (en) * | 1996-08-26 | 1998-03-10 | Shiseido Co Ltd | Vitamin e-vitamin c phosphoric diester/cyclodextrin clathrate and external preparation for skin containing the same |
| KR20000038845A (en) * | 1998-12-09 | 2000-07-05 | 이현순 | Improved stability of water in oil type emulsion cosmetic composition comprising l-ascorbic acid and manufacturing method thereof |
| JP2006008550A (en) * | 2004-06-23 | 2006-01-12 | Shiseido Co Ltd | Antiaging agent |
| JP2007055943A (en) * | 2005-08-25 | 2007-03-08 | Kyoei Kagaku Kogyo Kk | Ascorbic acid 2-phosphate magnesium composition and cosmetic containing the same |
| CN101938988A (en) * | 2008-02-08 | 2011-01-05 | 株式会社资生堂 | Skin whitening agent and external preparation for the skin |
| CN101757621A (en) * | 2008-11-28 | 2010-06-30 | 天津金耀集团有限公司 | Cyclodextrin inclusion drug composition for ocular inflammation resistance |
| KR20100127580A (en) * | 2009-05-26 | 2010-12-06 | (주)바이오제닉스 | Cosmetic composition having stabilized derivatives of vitamin c and method for fabricating the same |
| KR20120041074A (en) * | 2010-10-20 | 2012-04-30 | 주식회사 동구제약 | Pharmaceutical composition containing ascorbic acid and tranexamic acid having enhanced stability |
| CN102274145A (en) * | 2011-08-05 | 2011-12-14 | 广东南方洁灵科技实业有限公司 | Composite cyclodextrin clathrate of licorice flavones and ferulic acid and preparation method and applications thereof |
| US20180116986A1 (en) * | 2016-10-28 | 2018-05-03 | Hemant N. Joshi | Composition of novel powder formulations of tranexamic acid |
| CN108295080A (en) * | 2018-03-15 | 2018-07-20 | 山东滨州智源生物科技有限公司 | A kind of preparation method of salicylic acid HYDROXYPROPYL BETA-CYCLODEXTRIN inclusion compound |
Non-Patent Citations (3)
| Title |
|---|
| R: "ZA (姬芮)Total Hydration BB Cream UV White", 《HTTP://WWW.COSDNA.COM/CHS/COSMETIC_07C3104789.HTML》 * |
| 安伟娟等: "白藜芦醇-羟丙基-β -环糊精包合物的制备及鉴定", 《河北农业大学学报》 * |
| 陆彬: "《药物新剂型与新技术》", 31 May 2005, 人民卫生出版社 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113559005A (en) * | 2021-08-02 | 2021-10-29 | 成都卓阳生物科技有限公司 | Tranexamic acid glutathione compound aqueous solution and preparation method thereof |
| CN113559005B (en) * | 2021-08-02 | 2023-08-04 | 成都卓阳生物科技有限公司 | Tranexamic acid glutathione composite water agent and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104414869B (en) | A kind of skin and/or hair whitening mixture | |
| CN100459970C (en) | Skin whitening composition having synergic whitening effect | |
| JP2008526963A (en) | Compositions and methods for treating overpigmented skin | |
| CN108125803A (en) | A kind of whitening spot-eliminating composition | |
| CN109846785A (en) | A kind of solvable micropin and preparation method thereof with spot-removing function | |
| KR20140008234A (en) | Whitening cosmetic compounds | |
| WO2002005757A1 (en) | External preparations for beautifying the skin | |
| US20070172431A1 (en) | Methods, systems and compositions for skin care | |
| CN110507582A (en) | A kind of anti-ageing remediation composition and its preparation method and application containing composite vegetables extractive | |
| CN115634282A (en) | Application of mussel mucin product in treating and preventing melanin-related diseases | |
| US20110236503A1 (en) | Topical Skincare Composition | |
| CN100484509C (en) | Use of C-glycosides for depigmenting skin | |
| CN107530273A (en) | Composition containing Valerian root P.E | |
| JP5329830B2 (en) | SCF secretion inhibitor and sebum secretion inhibitor | |
| CN101524317B (en) | Skin-care cosmetic containing nonane diacid for dispelling freckles | |
| CN109758379A (en) | A kind of compound blood coagulation acid composition and preparation method thereof, product | |
| CN112451400A (en) | Water-in-oil type multi-effect whitening face cream | |
| KR20090091505A (en) | Composition for skin whitening containing oxygen dissolving water | |
| CN109475482A (en) | Drug | |
| JP2000344653A (en) | Eraser for active oxygen and skin cosmetic | |
| CN113693966A (en) | Innovative whitening brightening freckle-removing cream and preparation method thereof | |
| KR20090003828A (en) | Hair tonic containing composite for growig hair and preventing fall-out of hair | |
| CN109010094A (en) | A kind of resveratrol beautifying face and moistering lotion cosmetics and preparation method | |
| CN108309818A (en) | Whitening cosmetics | |
| CN113116753B (en) | Rose essential oil face cream and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |